Me faces potential bankruptcy, raising concerns about the security of the genetic data of its 15 million customers and the ...

Me continues to face challenges in maintaining its revenue and captures growth. Click here to read why ME stock is a Sell.

Me (ME), the company that popularized consumer genetic testing, is facing significant financial and leadership challenges as ...

Biotech company 23andMe was once hailed as one of the most successful businesses selling DNA analysis services to anybody who ...

Over the past year, 23andMe set new corporate governance lows. CEO Anne Wojcicki now enters de facto “founder mode” after a ...

Once worth $6 billion, 23andMe has lost 98% of its value and is on the verge of being delisted from the Nasdaq. So what ...

Financial and security chaos at the once-pioneering genetic testing firm has intensified concerns about user data. Here's how ...

Me was one of the hottest startups of the 2000s, once valued at $6 billion. The company's DNA test kits became a viral ...

The implications of this sale are significant, raising concerns over data privacy and the potential misuse of sensitive ...

In 2023, 23andMe had a data breach the exposed millions of people ancestry data. The lawsuit that followed, has reached a $30 ...

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

For the last decade, 23andMe has been known worldwide for offering genetic testing, ancestry tracing and health information ...